Filter by: patients
Home > Community Treatment Reports and Side Effects > Gabapentin-Baclofen-Elavil topical Treatment Report
What is Gabapentin-Baclofen-Elavil topical?

Gabapentin-Baclofen-Elavil topical is a non-commercial compounded product used for the treatment of interstitial cystitis.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Interstitial Cystitis 1 1 Efficacy_major

See all 2 patients currently taking Gabapentin-Baclofen-Elavil topical

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Reported Dosages

  6 other daily 300 mg daily 1,500 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Gabapentin-Baclofen-Elavil topical (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe 1   Side effects too severe: 100%
Course of treatment ended 1   Course of treatment ended: 100%

See all 1 patient who’ve stopped taking Gabapentin-Baclofen-Elavil topical

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Gabapentin-Baclofen-Elavil topical

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Gabapentin-Baclofen-Elavil topical

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Gabapentin-Baclofen-Elavil topical

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Gabapentin-Baclofen-Elavil topical

Very
 0 0%
Somewhat
 0 0%
A little
 1 100%
Not at all
 0 0%

Cost

Paid out of pocket

Cost of Gabapentin-Baclofen-Elavil topical

$200+
 0 0%
$100-199
 0 0%
$50-99
 1 100%
$25-49
 0 0%
< $25
 0 0%

Report created on May 28, 2012.